[Practice changes in the management of major paediatric haemophilia]. / Changements de pratiques dans la prise en charge de l'hémophilie majeure en pédiatrie.

Recent therapeutic innovations are significantly changing the management of young children with severe haemophilia. A team from the University Hospital of Nice (06) introduced emicizumab, the first subcutaneous non-replacement therapy. Integrated into the multi-professional management of children and their families, this innovative therapeutic option has shown encouraging initial results. Experience sharing.

[Understanding haemostasis to improve its management]. / L'hémostase, comprendre c'est maîtriser.

Haemostasis represents all the complex and interdependent mechanisms which enable bleeding to stop. This process involves the vessel walls, platelets, coagulation factors and von Willebrand factor. In the event of a disorder, the specific characterisation of the condition is the first stage of the diagnosis. Treatment is mainly based on substitution. All these disorders and their complications require multidisciplinary and specialised care.

[The lead nurse in a paediatric haemostasis unit]. / L'infirmière référente en centre de traitement pédiatrique des troubles de l'hémostase.

In an approach of global collaboration, the lead nurse in a paediatric haemostasis unit uses her technical and educational role to participate in the management of the child's specific disorder. As a resource person, she coordinates the care and ensures the continuity of the child's care.